البورد الأمريكى فى الصيدلة الإكلينيكية لأمراض القلب

<p><strong>Content:</strong></p> <p><strong>Domain 1: Patient Management and Therapeutics (approx. 59%)</strong>:</p> <ol> <li>CV anatomy/physiology</li> <li>Epidemiology, pathophysiology, risk fa

  • البورد الأمريكى فى الصيدلة الإكلينيكية لأمراض القلب

Course Overview

Content:

Domain 1: Patient Management and Therapeutics (approx. 59%):

  1. CV anatomy/physiology
  2. Epidemiology, pathophysiology, risk factors, diagnosis, and treatment of the following chronic and/or acute disease states: Aortic dissection - Arrhythmias - Cardiac Tamponade - Dyslipidemia - Heart failure - Hypertension - Hypotension - Infective endocarditis - Ischemic heart disease - Myocarditis - Pericarditis - Peripheral arterial disease - Pulmonary hypertension - Shock - Thrombotic disorders - Valvular heart disease - Pharmacology, pharmacokinetics, pharmacodynamics, and pharmacogenomics of CV pharmacotherapies
  3. Lifestyle modifications (e.g., smoking cessation, exercise, diet)
  4. CV procedures (e.g., cardioversion, ablation, PCI, CABG, cardiac transplantation)
  5. Device therapy (e.g., pacemaker, IABP, ICDs, LVADs)
  6. Laboratory testing specific to cardiology (e.g., troponin, BNP, platelet testing, genomic testing, INR)
  7. Diagnostic testing specific to cardiology (e.g., echo, stress testing, cardiac catheterization, ECG)
  8. Drug induced or exacerbation of CV diseases
  9. Risk stratification scores
  10. Hemodynamic monitoring
  11. CV-specific physical assessments (e.g., weight changes, presence of edema, breath sounds)
  12. Monitoring parameters for therapeutic efficacy and adverse effects of CV pharmacotherapies
  13. Documentation procedures
  14. Patient counseling and education techniques
  15. Collaboration strategies and techniques
  16. Communication strategies and techniques
  17. Drug interactions with CV pharmacotherapies
  18. Complementary and alternative medicines and their effects on CV health
  19. Patient-specific considerations (e.g., age, gender, ethnicity, comorbidities, socioeconomic status)
  20. Pharmacoeconomic considerations
  21. Patient assistance programs
  22. Facilitation of transitions of care

 Domain 2: Information Management and Education (approx. 23%)

  1. Primary, secondary, and tertiary sources of cardiovascular-related information
  2. Research design and methodology of cardiovascular-related trials
  3. Biostatistical methods used in cardiovascular-related trials
  4. Internal and external validity of cardiovascular-related trials
  5. Cardiovascular study endpoints (e.g., composite, surrogate)
  6. Opportunities for disseminating CV knowledge (e.g., publications, presentations)
  7. Audience-specific medical writing
  8. Roles of multidisciplinary CV team members
  9. Principles and methods of educating, training and mentoring practicing pharmacists and pharmacy trainees

Domain 3: Practice Development and Administration (approx. 14%)

  1. Accreditation, legal, regulatory and safety requirements related to the care of cardiovascular patients (e.g., The Joint Commission requirements, ASHP standards, Center for Medicare and Medicaid Services, National Committee for Quality Assurance, State Boards of Pharmacy, US Food and Drug Administration) Methods for identifying areas for process improvement (e.g., incident reports, chart review)
  2. Quality improvement techniques/methods (e.g., MUE, root cause analysis)
  3. Metrics for evaluating the value of cardiology pharmacy services (e.g., clinical, economic and patient experience)
  4. Pharmacoeconomics of cardiovascular therapies
  5. Clinical practice guidelines for the treatment of patients with or at risk for cardiovascular disease (e.g., AHA/ACCF, HFSA, ACCP, NHLBI)
  6. Principles of formulary development and management, including strategies for managing drug shortages Capabilities and limitations of electronic health information systems
  7. Methods for developing, implementing, and evaluating clinical pathways, protocols, and policies

Domain 4: Public Health and Patient Advocacy (approx. 4%)

  1. CV health promotion, disease prevention, and risk reduction strategies
  2. Public health information resources regarding CV health, prevention, and treatment
  3. CV screening techniques and application of results
  4. Healthcare delivery systems (e.g., Medicare, Medicaid, private insurance) as they impact access to care and treatment for CV patients
  5. Pharmacy advocacy organizations (e.g., ASHP, ACCP, APhA)
  6. Professional organizations and their roles and resources related to patient advocacy (e.g., ACC, AHA, HFSA)
  7. Health literacy considerations in CV public health initiatives

بعد الإعلان لأول مرة عن تخصص الصيدلة الإكلينيكية فى مجال أمراض القلب من البورد الامريكى للصيدلة الإكلينيكية فى بداية 2018...إحجز مكانك الان فى أول مجموعة دراسية فى العالم العربى للتاهيل للحصول على البورد الأمريكى لصيدلة أمراض القلب و كن من أوائل حاملى هذه الشهادة فى العالم.

Look at Our Latest Courses

You Can Suggest a New Course